Skip to main content

Table 3 Patients with immune-related liver injury

From: Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

35 patients

n (%)

CTCAE grade (n)

 1/2/3/4/5

7/9/14/4/1

Tumor type (n)

 Hep/Chol/Mix (grade ≥ 2)

16/10/2

 Liver biopsy

7 (20.0)

 Anti-PD-1 antibody

6

 Combination therapy

1

Treatment

 Prednisolone

18 (51.4)

 Ursodeoxycholic acid

6 (17.1)

 Mycophenolate mofetil

3 (8.6)

Withdrawal of ICIs

26 (74.3)

  1. PD-1 programmed death 1, Hep Hepatocellular-type, Chol cholestatic-type, Mix mixed-type
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us